Novel Anti-Cancer Therapies and Cardiac Outcomes :Systematic Reviews

Background Noval oncological therapies as chemotherapeutic drugs, immunotherapeutic, olecular target therapy and radiotherapies have improve cancer survivorship by potentially life-saving. These noval anti-neoplastic therapies have a significant adverse outcomes, particularly cardiotoxicity which prevent patients from complete receiving cancer treatment and so increase morbidity and mortality rate. Cardiovascular disease is the leading cause of noncancer deaths. Cardiovascular disease and cancer consider as the first and second most common cause of the burden of disease and death. Nowadays they are highly recognized and its drawback prevention remains challenging in cancer survivorship . Development of cadiovascular affection is associated with multiple modifiable risk factors including obesity, hypertension , diabetes, alcohol consumption, smoking, age, chronic kidney disease. Pre-assessment of those patients most likely to be given the cardioprotective therapy to improve cardiac outcomes in patients with preexisting heart disease . Objective to thorough the light on the importance of assessment of cardiac status before beginning in anti-cancer therapies to avoid cardiotoxicity . Methods a systematic literature review depends on collecting data from an evidence-based studies.Searches were made of forty electronic databases: the Cochrane Oral Health Group’s Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, PsycINFO, Scopus and Web of science, MEDLINE(PubMed). Results Systematic reviews have demonstrated correlation between anti cancer therapies and cardiovascular diseases (cardiotoxicity) especially with patients have a pre-existing risk factors . Conclusions Close collaboration among oncologists, hematologist , cardiologists, and primary care physicians to work together in a multidisciplinary setting for effective management of patients.